Key result
In patients with large hemispheric infarction, IV glyburide reduced deaths attributed to cerebral edema compared to placebo (2.4% vs 22.2%, p=0.01), despite no difference in malignant edema.
Why the study?
To evaluate the effect of IV glyburide on adjudicated, edema-related endpoints in patients with large hemispheric infarct.
Does IV glyburide reduce edema-related endpoints in patients with large hemispheric infarct?
RCT (n=77)
Double-blind
randomized
Does IV glyburide reduce edema-related endpoints in patients with large hemispheric infarct?
Absolute Event Rate: 58.5% vs 63.9%
p-value: p=0.91
In patients with large hemispheric infarction, IV glyburide may reduce edema-related deaths and improve clinical markers of cerebral edema.
No takes yet. Share an insight, caveat, or question.
Reduces edema-attributed deaths in large hemispheric infarction; extends targeted edema management options pending confirmation on malignant edema.
Kimberly et al. (2018) conducted an RCT in large hemispheric infarct (n=77). IV glyburide vs. placebo was evaluated on hemorrhagic transformation (p=0.91). In patients with large hemispheric infarction, IV glyburide reduced deaths attributed to cerebral edema compared to placebo (2.4% vs 22.2%, p=0.01), despite no difference in malignant edema.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: